First to See the Light

Trensant AI Acquired by Interos Solutions

GREENWICH, Conn./PRNewswire/ — Spencer Trask & Co., an advanced technology development firm, today announced that Interos Solutions, Inc. has acquired the patented Artificial Intelligence (AI) platform developed by its portfolio venture, Trensant, Inc. Interos provides supply chain risk assessment to major corporations and departments and agencies of the U.S. Federal government.

Trensant AI reads, processes and mines over 85,000 separate sources of data to distill information into a dynamic, live, connected knowledge graph. The system monitors more than 10 million companies, products, people, and events in near real-time. Trensant AI will enhance the ability of Interos to deliver quantitative and qualitative insights into supply chain risk for its customers.

“We enjoyed a strong relationship with Interos as our customer over the past year,” said Manjirnath (Manu) Chatterjee, CEO and Founder of Trensant. “It’s an incredible validation when a customer sees the value so strongly that they acquire the company. Our proprietary, automatic linked knowledge system will give Interos a broad ability to see interconnected supply chain risk in real time across multiple industries.”

“The acquisition of Trensant AI enhances our industry leading capabilities and will deliver additional value to our customers,” said Jennifer Bisceglie, CEO of Interos.

Neil Edwards, Chief Operating Officer of Trensant, connected the two companies. “Spencer Trask brought me into Trensant in 2017 to expand our customer base and monetize the business,” said Edwards. “We had several strategic options with Interos being the clear winner.”

About Spencer Trask & Co.
Spencer Trask & Co. is an advanced technology development firm, helping entrepreneurs, CEOs and corporate partners start and grow high impact ventures. The firm has been instrumental in launching market leaders in artificial intelligence, genomics, healthcare technology, mobile technology, the Internet and open innovation. Please visit for more information.

About Trensant
Founded by experts in physics, artificial intelligence and data science, Trensant is a pioneer in machine learning algorithms and artificial intelligence capabilities. The Trensant AI platform makes connections and provides unique insights for its clients.

The Immune Response Corporation

Revolution in Immunotherapy

DISCOVERY – Non-infectious viral vaccines.

INNOVATOR – In the history of medicine, few figures have had as profound an impact on human health and wellbeing as Dr. Jonas Salk. His polio vaccine breakthrough was the culmination of centuries of research, dating back to Louis Pasteur discovering inoculation. However, Salk’s method was different. He found a way to protect people from viruses without giving them the very disease the vaccine was designed to prevent.

Using this no-infection method, Salk worked with Kevin Kimberlin of Spencer Trask to develop cancer vaccines and an immunotherapeutic to slow or prevent AIDS. They patented and conducted preclinical studies on a cancer vaccine that demonstrated a startling 90% protection against lethal malignancies. 

IMPACT – A fusion of dendritic cells and the cancer antigen, their technology formed the basis for the first FDA-approved cell-based immunotherapy. Over 40,000 men with metastatic castrate-resistant prostate cancer have received the treatment, and it appears especially effective for African-American men who receive a 48% improved survival benefit compared to white men.

The team and facility making this immunotherapy also made clinical and commercial supplies of the first approved gene therapy, the CAT-T drug Kymriah.

The first approved cell-base immunotherapy and gene therapy prompted the FDA Commissioner to say, “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

The noninfectious vaccine approach developed by Jonas Salk eliminated polio from the developed countries, his flu vaccine mitigated the effects of influenza for the past 75 years, and finally, the cancer vaccine developed at his Immune Response Corporation led the way to gene, cell-based, and immune therapy innovations that will impact human health for generations. In summary, Salk released the last step in enabling the most important preventative medicine – non-infectious viral vaccination.